Ahn Joseph C, Lee Yi-Te, Agopian Vatche G, Zhu Yazhen, You Sungyong, Tseng Hsian-Rong, Yang Ju Dong
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095, USA.
Hepatoma Res. 2022;8. doi: 10.20517/2394-5079.2021.131. Epub 2022 Mar 11.
Hepatocellular carcinoma (HCC) is among the leading causes of cancer incidence and mortality worldwide. Surveillance of individuals with cirrhosis or other conditions that confer a high risk of HCC development is essential for early detection and improved overall survival. Biannual ultrasonography with or without alpha-fetoprotein is widely recommended as the standard method for HCC surveillance, but it has limited sensitivity in early disease and may be inadequate in certain individuals. This review article will provide a comprehensive overview of the current landscape of HCC surveillance, including the rationale and indications for HCC surveillance, standard methods for HCC surveillance, and their strengths/limitations. Alternative surveillance methods such as the role of cross-sectional imaging, emerging circulating biomarkers, as well as the problem of under-utilization of HCC surveillance and surveillance-related harms will also be discussed in this review.
肝细胞癌(HCC)是全球癌症发病率和死亡率的主要原因之一。对肝硬化或其他具有HCC发生高风险的个体进行监测对于早期发现和提高总体生存率至关重要。广泛推荐每半年进行一次超声检查(无论是否联合甲胎蛋白)作为HCC监测的标准方法,但它在疾病早期的敏感性有限,并且在某些个体中可能不足。这篇综述文章将全面概述HCC监测的当前情况,包括HCC监测的基本原理和适应症、HCC监测的标准方法及其优势/局限性。本综述还将讨论替代监测方法,如断层成像的作用、新兴的循环生物标志物,以及HCC监测利用不足和监测相关危害的问题。